Interleukin 12 immunotherapy after autologous stem cell transplantation for hematological malignancies

Clinical Cancer Research

Volumn 8, Issue 11, 2002, Pages 3383-3393

  Robertson, Michael J ^a   Pelloso, David ^a   Abonour, Rafat ^a   Hromas, Robert A ^a   Nelson, Robert P ^a   Wood, Lisa ^a   Cornetta, Kenneth ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; RECOMBINANT PROTEIN; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARMUSTINE; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; MELPHALAN; RECOMBINANT INTERLEUKIN 12;

ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; BLOOD; BLOOD DISEASE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HODGKIN DISEASE; HUMAN; IMMUNOTHERAPY; KINETICS; MALE; MAXIMUM TOLERATED DOSE; METABOLISM; METHODOLOGY; MIDDLE AGED; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PLASMACYTOMA; STEM CELL TRANSPLANTATION; TIME; ANEMIA; AUTOLOGOUS BONE MARROW TRANSPLANTATION; B LYMPHOCYTE; BLEEDING; CANCER IMMUNOTHERAPY; CHILL; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HEMATOLOGIC MALIGNANCY; HOSPITAL PATIENT; HYPERGLYCEMIA; LEUKOPENIA; LIVER FUNCTION TEST; LYMPHOCYTOPENIA; MOTOR DYSFUNCTION; NATURAL KILLER CELL; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OUTPATIENT; PRIORITY JOURNAL; SENSORY DYSFUNCTION; T LYMPHOCYTE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; CD4-POSITIVE T-LYMPHOCYTES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOLOGIC NEOPLASMS; HODGKIN DISEASE; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-12; KINETICS; LYMPHOMA, NON-HODGKIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PLASMACYTOMA; RECOMBINANT PROTEINS; STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 0036847429     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Attal, M., Harousseau, J-L., Stoppa, A-M., Sotto, J-J., Fuzibet, J-G., Rossi, J-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C., and Bataille, R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in myeloma. N. Engl. J. Med., 335: 91-97, 1996
2. Philip, T., Armitage, J. O., Spitzer, G., Chauvin, F., Jagannath, S., Cahn, J-Y., Colombat, P., Goldstone, A. H., Gorin, N. C., Flesh, M., Laporte, J-P., Maraninchi, D., Pico, J., Bosly, A., Anderson, C., Schots, R., Biron, P., Cabanillas, F., and Dicke, K. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N. Engl. J. Med., 316: 1493-1498, 1987
3. Guglielmi, C., Gomez, F., Philip, T., Hagenbeek, A., Martelli, M., Sebban, C., Milpied, N., Bron, D., Cahn, J-Y., Somers, R., Sonneveld, P., Gisselbrecht, C., van der Lelie, H., and Chauvin, F. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma Trial. J. Clin. Oncol., 16: 3264-3269, 1998
4. Linch, D. C., Winfield, D., Goldstone, A. H., Moir, D., Hancock, B., McMillan, A., Chopra, R., Milligan, D., and Hudson, G. V. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet, 341: 1051-1054, 1993
5. Yuen, A. R., Rosenberg, S. A., Hoppe, R. T., Halpern, J. D., and Horning, S. J. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood, 89: 814-822, 1997
6. Johnston, L. J., and Horning, S. J. Autologous hematopoietic stem cell transplantation for Hodgkin's disease. Biol. Blood Marrow Transplant., 6: 289-300, 2000
7. Horning, S. J., Chao, N. J., Negrin, R. S., Hoppe, R. T., Long, G. D., Hu, W. W., Wong, R. M., Brown, B. W., and Blume, K. G. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices. Blood, 89: 801-813, 1997
8. Chopra, R., McMillan, A. K., Linch, D. C., Yuklea, S., Taghipour, G., Pearce, R., Patterson, K. G., and Goldstone, A. H. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease: A single center eight-year study of 155 patients. Blood, 81: 1137-1145, 1993
9. Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., van der Lelie, H., Bron, D., Sonneveld, P., Gisselbrecht, C., Cahn, J-Y., Harousseau, J-L., Coiffier, B., Biron, P., Mandelli, F., and Chauvin, F. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N. Engl. J. Med., 333: 1540-1545, 1995
10. Vose, J. M., Anderson, J. R., Kessinger, A., Bierman, P. J., Coccia, P., Reed, E. C., Gordon, B., and Armitage, J. O. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J. Clin. Oncol., 11: 1846-1851, 1993
11. Vesole, D. H., Tricot, G., Jagannath, S., Desikan, K. R., Siegel, D., Bracy, D., Miller, L., Cheson, B., Crowley, J., and Barlogie, B. Autotransplants for multiple myeloma: What have we learned? Blood, 88: 838-847, 1996
12. Lenhoff, S., Hjorth, M., Holmberg, E., Turesson, I., Westin, J., Nielsen, J. L., Wisloff, F., Brinch, L., Carlson, K., Carlsson, M., Dahl, I-M., Gimsing, P., Hippe, E., Johnsen, H., Lamvik, J., Lofvenberg, E., Nesthus, I., and Rodjer, S. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: A population-based study. Blood, 95: 7-11, 2000
13. Brunda, M. J., Luistro, L., Warrier, R. R., Wright, R. B., Hubbard, B. R., Murphy, M., Wolf, S. F., and Gately, M. K. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med., 178: 1223-1230, 1993
14. Nastala, C. L., Edington, H. D., McKinney, T. G., Tahara, H., Nalesnik, M. A., Brunda, M. J., Gately, M. K., Wolf, S. F., Schreiber, R. D., Storkus, W. J., and Lotze, M. T. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol., 153: 1697-1706, 1994
15. Dranoff, G., Jaffee, E., Lazenby, A., Golumbeck, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R. C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony stimulating factor stimulates potent, long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA, 90: 3539-3543, 1993
16. Chen, K., Braun, S., Lyman, S., Fan, Y., Traycoff, C. M., Wiebke, E. A., Gaddy, J., Sledge, G., Broxmeyer, H. E., and Cornetta, K. Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer Res., 57: 3511-3516, 1997
17. Majolino, I., Pearce, R., Taghipour, G., and Goldstone, A. Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: A new matched-pair analysis of the European Group for Blood and Marrow Transplantation. J. Clin. Oncol., 15: 509-517, 1997
18. Desikan, R., Barlogie, B., Sawyer, J., Ayers, D., Tricot, G., Badros, A., Zangari, M., Munshi, N., Anaissie, E., Spoon, D., Siegel, D., Jagannath, S., Vesole, D., Epstein, J., Shaughnessy, J., Fassas, A., Lim, S., Robertson, P., and Crowley, J. Results of high-dose therapy for 1000 patients with multiple myeloma: Durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood, 95: 4008-4010, 2000
19. Dazzi, F., Szydlo, R. M., Cross, N. C. P., Craddock, C., Kaeda, J., Kanfer, E., Cwynarski, K., Olavarria, E., Yong, A., Apperley, J. F., and Goldman, J. M. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood, 96: 2712-2716, 2000
20. Collins, R. H., Jr., Shpilberg, O., Drobyski, W. R., Porter, D. L., Giralt, S., Champlin, R., Goodman, S. A., Wolff, S. N., Hu, W., Verfaillie, C., List, A., Dalton, W., Ognoskie, N., Chetrit, A., Antin, J. H., and Neumanitis, J. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol., 15: 433-444, 1997
21. Kolb, H-J., Schattenberg, A., Goldman, J. M., Hertenstein, B., Jacobsen, N., Arcese, W., Ljungman, P., Ferrant, A., Verdonck, L., Niederwieser, D., van Rhee, F., Mittermueller, J., deWitte, T., Holler, E., and Ansari, H. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood, 86: 2041-2050, 1995
22. Trinchieri, G. Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol., 13: 251-276, 1995
23. Hendrzak, J. A., and Brunda, M. J. Interleukin-12: Biologic activity, therapeutic utility, and role in disease. Lab. Investig., 72: 619-637, 1995
24. Gately, M. K., Wolitzky, A. G., Quinn, P. M., and Chizzonite, R. Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell. Immunol., 143: 127-142, 1992
25. Gately, M. K., Warrier, R. R., Honasoge, S., Carvajal, D. M., Faherty, D. A., Connaughton, S. E., Anderson, T. D., Sarmiento, U., Hubbard, B. R., and Murphy, M. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-γ in vivo. Int. Immunol., 6: 157-167, 1994
26. + T lymphocytes. J. Immunol., 151: 2444-2452, 1993
27. H1 cells. Immunol. Today, 14: 335-338, 1993
28. Robertson, M. J., Soiffer, R. J., Wolf, S. F., Manley, T. J., Donahue, C., Young, D., Herrmann, S. H., and Ritz, J. Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): Cytolytic activity and proliferation of NK cells is differentially regulated by NKSF. J. Exp. Med., 175: 779-788, 1992
29. + NK cells. J. Immunol., 148: 2429-2436, 1992
30. Chehimi, J., Valiante, N. M., D'Andrea, A., Rengaraju, M., Rosado, Z., Kobayashi, M., Perussia, B., Wolf, S. F., Starr, S. E., and Trinchieri, G. Enhancing effect of natural killer cell stimulatory factor (NKSF/interleukin-12) on cell-mediated cytotoxicity against tumor-derived and virus-infected cells. Eur. J. Immunol., 23: 1826-1830, 1993
31. Lieberman, M. D., Sigal, R. K., Williams, N. N., II, and Daly, J. M. Natural killer cell stimulatory factor (NKSF) augments natural killer cell and antibody-dependent tumoricidal responses against colon carcinoma cell lines. J. Surg. Res., 50: 410-415, 1991
32. Kobayashi, M., Fitz, L., Ryan, M., Hewick, R. M., Clark, S. C., Chan, S., Loudon, R., Sherman, F., Perussia, B., and Trinchieri, G. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med., 170: 827-845, 1989
33. Chan, S. H., Perussia, B., Gupta, J. W., Kobayashi, M., Pospisil, M., Young, H. A., Wolf, S. F., Young, D., Clark, S. C., and Trinchieri, G. Induction of interferon γ production by natural killer cell stimulatory factor: Characterization of responder cells and synergy with other inducers. J. Exp. Med., 173: 869-879, 1991
34. Zou, J-P., Yamamoto, N., Fujii, T., Takenaka, H., Kobayashi, M., Herrmann, S. H., Wolf, S. F., Fujiwara, H., and Hamaoka, T. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: Response is correlated with a striking reversal of suppressed IFN-γ production by anti-tumor T cells. Int. Immunol., 7: 1135-1145, 1995
35. Mu, J., Zou, J-P., Yamamoto, N., Tsutsui, T., Tai, X-G., Kobayashi, M., Herrmann, S., Fujiwara, H., and Hamaoka, T. Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res., 55: 4404-4408, 1995
36. Atkins, M. B., Robertson, M. J., Gordon, M., Lotze, M. T., DeCoste, M., DuBois, J. S., Ritz, J., Sandler, A. B., Edington, H. D., Garzone, P. D., Mier, J. W., Canning, C. M., Battiato, L., Tahara, H., and Sherman, M. L. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res., 3: 409-417, 1997
37. Motzer, R. J., Rakhit, A., Schwartz, L. H., Olencki, T., Malone, T. M., Sandstrom, K., Nadeau, R., Parmar, H., and Bukowski, R. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin. Cancer Res., 4: 1183-1191, 1998
38. Gollob, J. A., Mier, J. W., Veenstra, K., McDermott, D. F., Clancy, D., Clancy, M., and Atkins, M. B. Phase I trial of twice-weekly intravenous interleukin-12 in patients with metastatic renal cell cancer or melanoma: Ability to maintain IFN-γ induction is associated with clinical response. Clin. Cancer Res., 6: 1678-1692, 2000
39. Robertson, M. J., Caligiuri, M. A., Manley, T. J., Levine, H., and Ritz, J. Human natural killer cell adhesion molecules: Differential expression after activation and participation in cytolysis. J. Immunol., 145: 3194-3201, 1990
40. Harris, N. L., Jaffee, E. S., Stein, H., Banks, P. M., Chan, J. K. C., Cleary, M. L., Delsol, G., de Wolf-Peeters, C., Falini, B., Gatter, K. C., Grogan, T. M., Isaacson, P. G., Knowles, D. M., Mason, D. Y., Muller-Hermelink, H-K., Pileri, S. A., Piris, M. A., Ralfkiaer, E., and Warnke, R. A. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood, 84: 1361-1392, 1994
41. Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N. L., Armitage, J. O., Carter, W., Hoppe, R., and Canellos, G. P. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J. Clin. Oncol., 17: 1244-1253, 1999
42. Koehne, G., Zeller, W., Stockschlaeder, M., and Zander, A. R. Phenotype of lymphocyte subsets after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant., 19: 149-156, 1997
43. Guillaume, T., Rubinstein, D. B., and Symann, M. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood, 92: 1471-1490, 1998
44. Roberts, M. M., To, L. B., Gillis, D., Mundy, J., Rawling, C., Ng, K., and Juttner, C. A. Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation, and allogeneic bone marrow transplantation. Bone Marrow Transplant., 12: 469-475, 1993
45. Robertson, M. J., Cameron, C., Atkins, M. B., Gordon, M. S., Lotze, M. T., Sherman, M. L., and Ritz, J. Immunologic effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin. Cancer Res., 5: 9-16, 1999
46. Sykes, M., Szot, G. L., Nguyen, P. L., and Pearson, D. A. Interleukin-12 inhibits murine graft-versus-host disease. Blood, 86: 2429-2438, 1995
47. Yang, Y-G., Sergio, J. J., Pearson, D. A., Szot, G. L., Shimizu, A., and Sykes, M. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice. Blood, 90: 4651-4660, 1997
48. Soiffer, R. J., Robertson, M. J., Murray, C., Cochran, K., and Ritz, J. Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. Blood, 82: 2790-2796, 1993
49. Bajetta, E., Vecchio, M. D., Mortarini, R., Nadeau, R., Rakhit, A., Rimassa, L., Fowst, C., Borri, A., Anichini, A., and Parmiani, G. Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin. Cancer Res., 4: 75-85, 1998
50. Simpson, S. J., Shah, S., Comiskey, M., de-Jong, Y. P., Wang, B., Mizoguchi, E., Bhan, A. K., and Terhorst, C. T cell-mediated pathology in two models of experimental colitis depends predominantly on the interleukin 12/signal transducer and activator of transcription (Stat)-4 pathway, but is not conditional on interferon γ expression by T cells. J. Exp. Med., 187: 1225-1234, 1998
51. Weisdorf, D. J., Anderson, P. M., Blazar, B. R., Uckun, F. M., Kersey, J. H., and Ramsay, N. K. C. Interleukin 2 immediately after autologous bone marrow transplantation for acute lymphoblastic leukemia-a Phase I study. Transplantation, 55: 61-66, 1993
52. Robertson, M. J., and Ritz, J. Interleukin 12: Basic biology and potential applications in cancer treatment. Oncologist, 1: 93-102, 1996
53. Leonard, J. P., Sherman, M. L., Fisher, G. L., Buchanan, L. J., Larsen, G., Atkins, M. B., Sosman, J. A., Dutcher, J. P., Vogelzang, N. J., and Ryan, J. L. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-γ production. Blood, 90: 2541-2548, 1997
54. Arpinati, M., Green, C. L., Heimfeld, S., Heuser, J. E., and Anasetti, C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood, 95: 2484-2490, 2000
55. Guillaume, T., Sekhavat, M., Rubinstein, D. B., Hamdan, O., Leblanc, P., and Symann, M. L. Defective cytokine production following autologous stem cell transplantation for solid tumors and hematologic malignancies regardless of bone marrow or peripheral origin and lack of evidence for a role for interleukin-10 in delayed immune reconstitution. Cancer Res., 54: 3800-3807, 1994
56. Brunda, M. J., Luistro, L., Hendrzak, J. A., Fountoulakis, M., Garotta, G., and Gately, M. K. Role of interferon-γ in mediating the antitumor efficacy of interleukin-12. J. Immunother., 17: 71-77, 1995
57. Nakanishi, K., Yoshimoto, T., Tsutsui, H., and Okamura, H. Interleukin-18 regulates both Th1 and Th2 responses. Annu. Rev. Immunol., 19: 423-474, 2001